D1 dopamine receptors mediate neuroleptic-induced Fos expression in the islands of Calleja

Synapse
D Wirtshafter

Abstract

Systemic injections of the selective, full, D1 agonists A-77636 and SKF-82958 induced pronounced Fos-like immunoreactivity in the islands of Calleja in the olfactory tubercle of intact rats. Fos expression in this region could also be induced by injections of the D2-like dopamine antagonist raclopride (0.5 mg/kg). Pretreatment with the selective D1 dopamine antagonist SCH-23390 (0.2 mg/kg) completely abolished this response, but was without significant effect on raclopride-induced Fos expression in the dorsolateral region of the striatum. SCH-23390 was also able to prevent the atypical neuroleptic clozapine (30 mg/kg) from inducing Fos expression in the islands of Calleja. These findings demonstrate that stimulation of D1 dopamine receptors plays an essential role in neuroleptic induction of Fos-like immunoreactivity in the islands of Calleja, but not in the dorsal striatum, and thus suggest that different mechanisms underlie neuroleptic stimulation of immediate early gene expression in these two structures.

References

Sep 15, 1978·The Journal of Comparative Neurology·J H FallonR Y Moore
Dec 15, 1992·European Journal of Pharmacology·J W KebabianM Williams
Aug 1, 1991·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·H A RobertsonA M Graybiel
Apr 1, 1990·Journal of Neurochemistry·J C Miller
Feb 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S T YoungM J Iadarola
Sep 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·A M GraybielH A Robertson
Sep 22, 1988·The Journal of Comparative Neurology·K TalbotL L Butcher
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Nov 1, 1987·The Journal of Comparative Neurology·O E Millhouse
Mar 1, 1982·The Journal of Comparative Neurology·C E Ribak, J H Fallon
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·A M MurrayJ N Joyce
Apr 22, 1993·European Journal of Pharmacology·K E Asin, D Wirtshafter
Aug 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G J LaHosteJ F Marshall
Jun 20, 1996·European Journal of Pharmacology·P Salmi, S Ahlenius
Dec 10, 1996·Proceedings of the National Academy of Sciences of the United States of America·R MoratallaA M Graybiel

❮ Previous
Next ❯

Citations

Sep 2, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·M TremblayD Lévesque
Jun 6, 2002·Journal of Chemical Neuroanatomy·Noboru HiroiRosario Moratalla
May 6, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Jenny AhlqvistPeter Salmi
Oct 16, 2004·Journal of Chemical Neuroanatomy·David Wirtshafter, Catherine V Osborn
Dec 10, 2003·Neuroreport·David Wirtshafter, Karen E Asin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.